Last reviewed · How we verify
SI-722
At a glance
| Generic name | SI-722 |
|---|---|
| Sponsor | Seikagaku Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- COVID-19
- Urinary tract infection
- Diabetes mellitus inadequate control
- Nausea
- Genital herpes
- Glucose tolerance impaired
- Headache
- Back pain
- Muscle spasms
- Dysuria
- Procedural pain
Key clinical trials
- PK and Safety of SI-722 in IC/BPS (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SI-722 CI brief — competitive landscape report
- SI-722 updates RSS · CI watch RSS
- Seikagaku Corporation portfolio CI